PHA-665752
Overview[edit | edit source]
PHA-665752 is a small molecule inhibitor that targets the c-Met receptor tyrosine kinase. It is primarily studied for its potential therapeutic effects in treating various types of cancer, particularly those that exhibit overexpression or dysregulation of the c-Met pathway.
Mechanism of Action[edit | edit source]
PHA-665752 functions by selectively inhibiting the activity of the c-Met receptor. The c-Met receptor, also known as the hepatocyte growth factor receptor (HGFR), is involved in various cellular processes including proliferation, survival, and metastasis. Dysregulation of c-Met signaling is implicated in the progression of several cancers, making it a target for therapeutic intervention.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of PHA-665752 includes its absorption, distribution, metabolism, and excretion characteristics. Studies have shown that PHA-665752 is absorbed and distributed effectively in animal models, with a half-life that supports its potential use in clinical settings. The compound is metabolized primarily in the liver and excreted through renal pathways.
Clinical Research[edit | edit source]
Research on PHA-665752 has been conducted in preclinical models, demonstrating its efficacy in inhibiting tumor growth and metastasis in cancers such as non-small cell lung cancer, gastric cancer, and hepatocellular carcinoma. These studies have shown that PHA-665752 can reduce tumor size and prevent the spread of cancer cells by blocking c-Met signaling.
Potential Side Effects[edit | edit source]
As with many kinase inhibitors, potential side effects of PHA-665752 may include gastrointestinal disturbances, fatigue, and hematological abnormalities. Further clinical trials are necessary to fully elucidate the safety profile of this compound.
Future Directions[edit | edit source]
Ongoing research is focused on optimizing the efficacy and safety of PHA-665752, as well as exploring its use in combination with other therapeutic agents. The development of biomarkers to predict response to c-Met inhibitors is also an area of active investigation.
Also see[edit | edit source]
Template:Receptor tyrosine kinase inhibitors
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
